Seonix Bio launches SightScore testing service for primary open-angle glaucoma

(Image Credit: AdobeStock/Andrey Popov)

Seonix Bio has announced the commercial launch of SightScore, a clinical polygenic risk score testing service for primary open-angle glaucoma (POAG).

According to the company, SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma. The company states that the test estimates the patient’s genetic risk of developing glaucoma in the future, or it assesses the risk that the patient’s glaucoma might get worse if they have already been diagnosed. Furthermore, the company noted that current tools to determine who is at risk of glaucoma are based on family history, age, and eye tests like ocular pressure and imaging, but these tools lack sufficient predictive power to reliably triage patients.

Inder Paul Singh, president of The Eye Centers of Racine & Kenosha, Ltd., Kenosha, Wisconsin, commented on the availability of SightScore in a press release from the company.

“SightScore is a game changer in the way we will assess and manage patients at risk for glaucoma. It is an invaluable tool for identifying individuals who may not show obvious signs of the disease yet and are at higher genetic risk,” said Singh. “By incorporating SightScore into our practice, we can more effectively prioritize patients for early screening, personalize their care, and ensure we’re detecting glaucoma in its earliest, most treatable stages.”

SightScore is now available for clinicians in the US, in addition to Australia and New Zealand.

The spread of possible SightScore results is shown as a ‘bell curve,’ with most people near the middle and fewer people at the upper and lower risk ends (photo credit: Seonix Bio)

Reference:

1. Seonix Bio announces US launch of SightScore, the first commercially available clinical polygenic risk score testing service for glaucoma. Published February 20, 2025. Accessed February 20, 2025.https://www.businesswire.com/news/home/20250220762988/en/Seonix-Bio-Announces-US-Launch-of-SightScore-the-First-Commercially-Available-Clinical-Polygenic-Risk-Score-Testing-Service-for-Glaucoma